Each strip is engineered to dissolve quickly when placed against oral mucosa, providing a consistent delivery format for researchers evaluating buccal administration characteristics
The peptide is used clinically through compounding pharmacy channels
The SELECT trial showed that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity and established cardiovascular disease, without requiring a diabetes diagnosis. The FLOW trial showed kidney benefits with semaglutide use in patients with type 2 diabetes and chronic kidney disease. Improvements in hard clinical outcomes like cardiac events, kidney disease, and death are commonly observed with GLP-1 use, and are due to both the direct effects of treating the obesity, and indirect effects of the medications themselves
In these cases, switching to semaglutide may trigger renewed metabolic response because it activates a different primary pathway and can sometimes restart fat loss momentum
In particular, multi-omics approaches integrating metagenomics, metabolomics, and host transcriptomics may help elucidate the complex interactions between microbial metabolites and endocrinemetabolic pathways
10.3389/fimmu.2022.964901 20 Hye KhanM
